<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">Tumor lysis syndrome</z:e> (TLS) is defined by metabolic derangements occurring in the setting of rapid <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> destruction </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), TLS frequency, risk stratification, monitoring, and management strategies are based largely on case series and data from other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>A single-center, retrospective cohort study was conducted to estimate TLS incidence and identify TLS predictive factors in a patient population undergoing myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> induction chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>This study included 194 patients, aged 18-86 years, with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> undergoing primary myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> induction chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>Nineteen patients (9.8%) developed TLS </plain></SENT>
<SENT sid="5" pm="."><plain>In univariate analysis, elevated pre-chemotherapy values for <z:chebi fb="3" ids="27226">uric acid</z:chebi> (P &lt; 0.0001), <z:chebi fb="0" ids="16737">creatinine</z:chebi> (P = 0.0025), <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH) (P = 0.0001), white blood cell (P = 0.0058), gender (P = 0.0064) and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> history (P = 0.0292) were significant predictors </plain></SENT>
<SENT sid="6" pm="."><plain>In multivariate analysis, LDH (P = 0.0042), <z:chebi fb="3" ids="27226">uric acid</z:chebi> (P &lt; 0.0001) and gender (P = 0.0073) remained significant TLS predictors </plain></SENT>
<SENT sid="7" pm="."><plain>A predictive model was then designed using a scoring system based on these factors </plain></SENT>
<SENT sid="8" pm="."><plain>This analysis may lay the groundwork for the development of the first evidence-based guidelines for TLS monitoring and management in this patient population </plain></SENT>
</text></document>